Restoring Biological Harmony for Patients with Debilitating Disease

We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.

Learn More

DEVELOPMENT PROGRAMS

Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.

Learn More

Recent Press Releases

August 5, 2020: miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 4, 2020: miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
July 28, 2020: miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
July 23, 2020: Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
July 22, 2020: miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

View All